GlassScriptPhysician profile
Douglas G Starr
NPI 1154322998
$1,054.82
in general payments reported to CMS, 2019-2025
16 companies · $76.30 in 2025
The $76.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $95.00 · 2021: $24.46 · 2022: $204 · 2023: $166 · 2024: $169 · 2025: $76.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $238.40 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $131.05 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Novo Nordisk INC | $103.73 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $81.64 | 2019-2020 | |
| Amgen INC. | $78.64 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.18 | 2019-2025 | Airsupra |
| Pfizer INC. | $56.05 | 2023-2024 | |
| Abbvie INC. | $43.34 | 2021-2024 | |
| Esperion Therapeutics, INC. | $34.86 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $31.86 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.21 | 2023-2025 | Xifaxan |
| Allergan, INC. | $24.92 | 2019 | |
| Ibsa Pharma INC. | $22.85 | 2025 | Tirosint, Licart, Flector |
| Sanofi Pasteur INC. | $19.76 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.